Medicenna Therapeutics Corp continues to navigate a challenging market landscape, with recent developments and stock performance reflecting its ongoing journey.
This week, Medicenna Therapeutics Corp (MDNA.TO) saw a slight uptick in its stock price, gaining 1.25% over the week. However, the stock has faced significant challenges this year, down 59.50% year-to-date. With recent announcements and financial results, investors are closely watching the company's trajectory.
Advertisement
Medicenna Therapeutics Corp
MDNA.TO
MDNA.TO
Medicenna Therapeutics Corp
WealthAwesomeMarket cap
$37.38M
52W high
$1.97
52W low
$0.34
1W change
+1.25%
Beta
1.96
Analyst Price Targets
Based on analyst covering MDNA · as of Sep 17, 2026
Wall Street analysts forecast MDNA stock price to rise 690.1% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$3.20
+690.1% Upside
Current Price
C$0.41
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MDNA's historical volatility
30-Day Vol
64.9%
Annualized
90-Day Vol
57.0%
Annualized
Trend (90d)
+0.0%
Annualized drift
90d Mean
C$0.41
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.41 | C$0.32 – C$0.51 |
| 60 trading days | C$0.41 | C$0.30 – C$0.56 |
| 90 trading days | C$0.41 | C$0.27 – C$0.60 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: While Medicenna's stock has shown some resilience this week, its overall performance raises questions about its long-term viability in a competitive healthcare landscape. Investors should consider the recent developments and financial health as they assess potential risks and rewards.
Medicenna's Stock Down 59.50% YTD
The significant year-to-date decline highlights the challenges Medicenna faces in gaining traction within the healthcare sector, despite recent advancements.
Bull case
The company has recently strengthened its patent portfolio, which could give it a competitive edge in the market. Additionally, upcoming presentations at major investment conferences may attract attention and investment interest.
Bear case
Despite the recent announcements, Medicenna's financial performance remains concerning, with a negative return on equity and a substantial decline in stock price this year. The low trading volume compared to its average also suggests a lack of investor confidence.
Recent Price Action
Advertisement
Medicenna Therapeutics Corp closed at C$0.41, reflecting a daily decrease of 1.22%. Over the past week, the stock has shown a modest increase of 1.25%, although it remains significantly lower than its 52-week high of C$1.97.
Company News
This week, Medicenna announced its participation in the H.C. Wainwright 28th Annual Global Investment Conference, which could provide a platform for showcasing its developments. The company also reported its first-quarter fiscal 2027 financial results and highlighted operational achievements from the previous fiscal year. Notably, Medicenna has strengthened its U.S. patent estate with new patents, potentially enhancing its market position.
Technical Picture
From a technical perspective, Medicenna's stock is currently trading below both its 50-day moving average of C$0.40 and its 200-day moving average of C$0.65. The stock's 52-week range has been between C$0.34 and C$1.97, indicating that it is currently at 4% of its range. With a beta of 1.96, the stock exhibits higher volatility compared to the overall market. Recent trading volume has been notably low, with only 1,537 shares changing hands against a 20-day average volume of 44,322 shares, suggesting subdued investor interest.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
